umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Rituximab in paediatric onset multiple sclerosis: a case series
Umeå universitet, Medicinska fakulteten, Institutionen för farmakologi och klinisk neurovetenskap, Klinisk neurovetenskap.
Visa övriga samt affilieringar
2016 (Engelska)Ingår i: Journal of Neurology, ISSN 0340-5354, E-ISSN 1432-1459, Vol. 263, nr 2, s. 322-326Artikel i tidskrift (Refereegranskat) Published
Resurstyp
Text
Abstract [en]

Paediatric onset multiple sclerosis (POMS) is characterized by high inflammatory activity. No disease modifying treatment has been approved for POMS. The objective of this report was to report the use of rituximab, a B cell depleting monoclonal anti-CD20-antibody, in POMS. This is a retrospective case series at four specialized MS centres in Sweden. Participants were identified through the Swedish MS-registry and our own patient stocks. Data were collected through medical charts review. We identified 14 POMS patients treated with i.v. rituximab 500-1000 mg every 6th to 12th months. Median age at disease onset was 14.7 years, median age at rituximab treatment initiation was 16.5 years, and median treatment duration was 23.6 months. No relapses were reported, and the EDSS scores remained stable or decreased in 13 of 14 cases during rituximab treatment. Beyond 6 months from initiating rituximab treatment, only one new lesion was detected on MRI. No serious AEs were reported. The drug survival was 86 %. Our data indicate that rituximab treatment is safe, effective and well tolerated in children with MS. Nine POMS cases treated with rituximab have previously been published. They had higher disease activity pre-rituximab, but similar safety and efficacy outcomes after treatment. An RCT of rituximab in POMS is warranted.

Ort, förlag, år, upplaga, sidor
Springer Berlin/Heidelberg, 2016. Vol. 263, nr 2, s. 322-326
Nyckelord [en]
Paediatric onset multiple sclerosis, Observational study, Immunomodulatory treatment, Rituximab
Nationell ämneskategori
Neurologi
Identifikatorer
URN: urn:nbn:se:umu:diva-118255DOI: 10.1007/s00415-015-7979-xISI: 000370270100016PubMedID: 26603152OAI: oai:DiVA.org:umu-118255DiVA, id: diva2:912751
Tillgänglig från: 2016-03-17 Skapad: 2016-03-14 Senast uppdaterad: 2018-06-07Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Salzer, JonatanSvenningsson, Anders

Sök vidare i DiVA

Av författaren/redaktören
Salzer, JonatanSvenningsson, Anders
Av organisationen
Klinisk neurovetenskap
I samma tidskrift
Journal of Neurology
Neurologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 162 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf